Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
7700 participants
INTERVENTIONAL
2002-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zoledronic Acid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No history of severe liver, kidney or eye disease
Exclusion Criteria
* Using hip protectors
65 Years
89 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Arizona Arthritis Research
Paradise Valley, Arizona, United States
Southern Arizona VA
Tucson, Arizona, United States
University of Arkansas for Medical Science
Little Rock, Arkansas, United States
Osteoporosis Medical Center
Beverly Hills, California, United States
Orthopaedic Hospital
Los Angeles, California, United States
The Foundation for Osteoporosis Research and Education
Oakland, California, United States
University of California Davis- Gen Med Research
Sacramento, California, United States
Osteoporosis Prevention Center
San Diego, California, United States
Radiant Research- San Diego
San Diego, California, United States
Diablo Clinical Research, Inc
Walnut Creek, California, United States
Colorado Center for Bone Research
Lakewood, Colorado, United States
Longmont Medical Research Network
Longmont, Colorado, United States
Northeast Clinical Research
Hamden, Connecticut, United States
Health Core
Newark, Delaware, United States
CRA Research
Fort Lauderdale, Florida, United States
Anchor Research Center
Naples, Florida, United States
Sarasota Arthritis Center
Sarasota, Florida, United States
Radiant
Stuart, Florida, United States
Comprehensive Clinical Trials, LLC
West Palm Beach, Florida, United States
Palm Beach Research Center
West Palm Beach, Florida, United States
United Osteoporosis Centers (UOC)
Gainesville, Georgia, United States
Northwestern University Center for Clinical Research
Chicago, Illinois, United States
School of Medicine
Indianapolis, Indiana, United States
Medical Specialists
Munster, Indiana, United States
Heartland Research Associates, LLC
Wichita, Kansas, United States
Center for Arthritis and Osteoporosis
Elizabethtown, Kentucky, United States
Maine Center for Osteoporosis Research and Education
Bangor, Maine, United States
Osteoporosis Clinical Trial Center
Hagerstown, Maryland, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Clinical Pharmacology Study Groups
Worcester, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
Arthritis Regional Research Center
Mercerville, New Jersey, United States
Phoenix OB-GYN Associates, LLC
Moorestown, New Jersey, United States
New Mexico Clinical Research and Osteoporosis Center, Inc
Albuquerque, New Mexico, United States
Endwell Family Physicians
Endwell, New York, United States
Winthrop U Hospital
Mineola, New York, United States
Internal Medicine Associates
Fargo, North Dakota, United States
University of Cincinnati Bone Health and Osteoporosis Center
Cincinnati, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Einstein
Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Radiant
Wyomissing, Pennsylvania, United States
Rhode Island Hospital, Osteoporosis Research/ Bone Density Unit
Providence, Rhode Island, United States
Roger William Medical Center
Providence, Rhode Island, United States
Avera Research Institute
Sioux Falls, South Dakota, United States
University of Tennessee Health Science
Memphis, Tennessee, United States
West Cancer Clinic
Memphis, Tennessee, United States
Diabetes Regional Research Center
Midland, Texas, United States
Sam Clinical Research Center
San Antonio, Texas, United States
University of Texas Health Center at Tyler -Center for Clinical Research
Tyler, Texas, United States
Hampton Roads Center for Clinical Research, Inc
Norfolk, Virginia, United States
McGuire Veterans Affairs Medical Center
Richmond, Virginia, United States
VA Commonwealth University
Richmond, Virginia, United States
Osteoporosis Research Unit
Seattle, Washington, United States
The Physicians Clinic
Spokane, Washington, United States
Novartis
Nuremberg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cai G, Keen HI, Host LV, Aitken D, Laslett LL, Winzenberg T, Wluka AE, Black D, Jones G. Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2020 Sep;31(9):1741-1747. doi: 10.1007/s00198-020-05430-z. Epub 2020 May 2.
Mathew A, Brufsky A. Bisphosphonates do not reduce breast cancer in postmenopausal women. Ann Intern Med. 2015 Jan 20;162(2):JC5. doi: 10.7326/ACPJC-2015-162-2-005. No abstract available.
Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, Black DM. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med. 2014 Oct;174(10):1550-7. doi: 10.1001/jamainternmed.2014.3634.
Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; HORIZON Pivotal Fracture Group. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292.
Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010 Nov;141(11):1365-70. doi: 10.14219/jada.archive.2010.0082.
Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22. doi: 10.1056/NEJMoa067312.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CZOL446H2301
Identifier Type: -
Identifier Source: org_study_id